Navigation Links
Roche Submits Acute Hepatitis B Test to FDA for Premarket Approval
Date:7/26/2011

INDIANAPOLIS, July 26, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for the Elecsys Anti-HBc IgM assay for use on the cobas e 411, cobas e 601 and MODULAR ANALYTICS E170 analyzers. The hepatitis B test represents the final component of the acute panel within the hepatitis menu on Roche's family of immunoassay analyzers.

The PMA submission is for use of the assay in the in-vitro qualitative determination of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) in human serum or plasma.  The presence of anti-HBc IgM, in conjunction with other laboratory results and clinical information, is indicative of acute or recent hepatitis B virus (HBV) infection.* The assay is intended to be used with Roche's electrochemiluminescence (ECL) immunoassay technology.

Roche currently has seven other immunoassay tests available on its hepatitis menu:  HBsAg, HBsAg Confirmatory, Anti-HBs, Anti-HCV, Anti-HAV, Anti-HAV IgM and Anti-HBc.

The FDA has 45 days after the PMA is received to notify Roche whether the application has been filed. If the PMA is accepted for filing, the FDA has a 180-day period for substantive review of the application.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

* The Elecsys Anti-HBc IgM immunoassay's performance has not been established for the monitoring of HBV disease or therapy.

All trademarks used or mentioned in this release are protected by law.For further information, please contact: Betsy Cox Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN(317) 521-3911betsy.cox@roche.com
'/>"/>

SOURCE Roche Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Agri-Business Acquired Management and Operation Rights of Shaanxi Qinfeng Agrochemical Inc. in Xian, China
2. Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies
3. Roche Building Awarded LEED® Gold Certification
4. Rules-Based Medicine Reaches a Significant Milestone in Companion Diagnostic Program With Roche
5. Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children
6. Roche Diabetes Care in the U.S. Turns to Social Media to Promote Diabetes Education, Awareness and Advocacy
7. Pivotal Study Validates Roches cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer
8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
9. Roche, Baylor Research Institute Partner in Human Immunology Research
10. Roche Diabetes Care Forms Human Blue Circle, Supports Viral Video for World Diabetes Day
11. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of ... board-certified in surgery and surgery of the hand by the National Board of ... to going above and beyond in his pursuit of providing the most comprehensive, ...
(Date:5/25/2016)... ... ... Lady had been battling arthritis since the age of two and at the ... Hannah sought the help of Dr Jeff Christiansen of Superior Veterinary Surgical Solutions ... help with the pain of Lady’s arthritis. Dr Christiansen suggested that in conjunction with ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated ... entrepreneurs, held The Future of San Diego Life Science event at the Estancia La ... community attended the event with speakers Dr. Rich Heyman, former CEO of Aragon and ...
(Date:5/23/2016)... 23, 2016 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2016. The cash dividend of $0.24 ... 2016 to stockholders of record as of the close of ... subject to approval of the Board of Directors and may ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):